put togeth right part organ growth initi coverag buy pt
receiv cash proce warrant
integr portfolio organ growth initi coverag
buy rate price target share aytu bioscienc inc
bullish aytu share base follow three point
acquisit pediatr
portfolio asset creat co-promot partnership cross-sel
opportun potenti aytu portfolio legaci product
form platform diversifi futur revenu growth
potenti distribut right rapid diagnost test kit
creat valuabl near-term revenu opportun aytu
establish right distribut rapid test
therefor creat potenti valuabl futur revenu opportun
view avail rapid test mere play
opportun focu aytu potenti organ
growth fully-integr specialti pharmaceut compani
underappreci valu proposit look rapid test valid
result posit catalyst stock
recent acquisit creat co-promot partnership cross-
sell opportun acquisit asset cerecor
nine
differenti product innovu acquisit enabl entri
non-rx consum health market addit innovu portfolio
product month end septemb
record revenu innovu acquir
aggreg aytu common stock
consum health revenu fiscal believ aytu track
deliv signific return consum health portfolio alon
thu base pro forma compani revenu believ aytu
achiev annual revenu combin organ growth
innovu consum health product pediatr product
aytu legaci product thu believ back-to-back acquisit
product portfolio innovu posit aytu cater
rx non-rx product segment could gener signific
momentum sustain revenu growth
expect aytu legaci product form basi revenu
divers aytu legaci portfolio includ natesto fda-
approv nasal formul testosteron zolpimist fda-
approv oral spray prescript sleep aid tuzistra xr
fda-approv codeine-bas antituss syrup
last six month compani initi sever co-promot
activ bode well expand legaci product market reach
optim sg aytu amend partnership term
royalti payment co-promot sales-bas commiss
natesto ascpf rate
agre fund launch us-bas sale forc rep
intend market natesto urologist endocrinologist
meant expand natesto promot footprint enabl aytu
increas promot effort primari care specialti
segment recent announc equiti infus
drive natesto growth believ favor new
commiss structur translat higher gross
profit lower mileston payment regulatori fee clinic trial
expens separ also agre assum regulatori
clinic respons associ expens
definit distribut analyst rate analyst certif disclosur pleas refer page report
entri arena mere serendipit opportun particip expand pandem test
capabl march aytu garner notorieti compani join list compani
larg well-establish diagnost test maker offer serolog rapid diagnost test kit aytu igg-igm
rapid test kit import china gain formal fda approv commerci
gain emerg use author eua approv grant limit number product whose short-term use
medic countermeasur public health emerg pandem need aytu rapid test
licens ltd lbr hong kong corpor in-licens right develop zhejiang
orient gene biotech co ltd zogb opportun came aytu attent relationship lbr aytu
consult asset in-licens grow product portfolio think import note fda
issu initi polici februari use coronaviru diagnost test fda specifi critic
agenc provid regulatori flexibl serolog test develop understand test meant
use sole basi diagnosi coronaviru antibodi test subsequ enter
market includ aytu igg/igm rapid test kit view aytu success acquir right zogb rapid test natur
extens busi strategi
posit independ test valid give aytu rapid test credibl rapid test initi evalu sensit
specif igg igm guangzhou institut respiratori health april independ evalu
accuraci specif perform compani test antibodi novel coronaviru cov
caus pandem publish scientif journal infect ecolog epidemiolog reveal sensit
igm igg respect specif igm igg respect
igm test clear util diagnosi person first infect pathogen igm level rise short time
infect test igm suffer disproportion false-posit result contrast igg common type
antibodi associ immun system memori previou exposur pathogen like thu
sensit aytu rapid test igm low believ sensit specif igg robust versu rapid
igg test demonstr sensit specif rang igg therefor believ
data strong enough gain futur eua aytu rapid test look clinic studi lead eua aytu
rapid test end posit catalyst
aytu rapid test repres near-term opportun potenti becom long-term recur revenu
expect see list coronaviru test eua grow thu expect aytu compet mani larg player diagnost
serolog roch rhhbi rate abbott rate whose distribut channel brand name recognit
well sale market budget signific challeng result aytu test busi could
near-term opportun long remain shortag cov test howev littl test conduct
 popul believ diagnost market present ampl potenti futur growth
thu room multipl player therefor believ distribut aytu test earli march posit
take advantag signific near-term market opportun notabl first test aytu offer quickli
purchasedevid huge unmet demand therefor even small penetr market would substanti
impact compani revenu believ aytu rel small size compar peer work favor
therefor potenti long-term recur revenu underappreci
valuat risk pt deriv use weighted-averag cost capit aytu bioscienc share
discount free cash flow project divid project number share year account
effect share dilut ascrib termin growth rate probabl success latter
repres broad assess risk across compani revenu look aytu financ date
averag price result year-end share count share risk invest thesi includ failur
clinic trial regulatori requir addit clinic studi commerci strategi failur product show
suffici competit differenti target product indic intellectu properti expiri invalid potenti
rais addit fund poor market condit
aytu bioscienc inc aytu nasdaq-list commercial-stag specialti pharmaceut compani
engag acquisit develop commerci novel therapeut across rang
indic compani mainli focus treatment hypogonad male infertil
upper respiratori allergi insomnia recent back-to-back acquisit innovu pediatr
product portfolio buy selvaraju provid greater diversif portfolio
hous brand over-the-count over-the-counter non-prescript consum care product
found august rosewind corpor compani began oper april
rosewind merger vyrix pharmaceut luoxi diagnost june rosewind
reincorpor chang name aytu bioscienc inc headquart englewood colorado
octob aytu up-list otcqx otcqb share trade
aytu legaci portfolio includ natesto fda-approv nasal formul testosteron
zolpimist fda-approv oral spray prescript sleep aid tuzistra xr fda-
approv codeine-bas antituss syrup pediatr portfolio acquir cerecor
includ aciphex sprinkl granul formul rabeprazol sodium activ pharmaceut
ingredi commonli prescrib gener proton pump inhibitor cefaclor second-gener
cephalosporin antibiot suspens karbin er extended-releas carbinoxamin antihistamin
suspens indic treatment numer allerg condit poly-vi-flor tri-vi-flor
two complementari fluoride-bas supplement product line compris combin fluorid
vitamin infant children fluorid defici compani product portfolio also includ
over-the-counter consum product acquisit innovu addit aytu pursu
fda approv mioxsi compani novel vitro diagnost system male infertil assess
caus oxid stress though mioxsi alreadi commerci outsid exampl
eu ce mark approv commerci health canada australian tga
mexican cofepra aytu eye fda approv fda de novo medic devic
year aytu expand target custom base slew in-licens agreement
acquisit novel product expect acquisit futur creat valu overal
believ aytu busi model consider de-risk primarili target late-stag product
candid alreadi approv product significantli mitig product develop risk
potenti posit compani steadi inflow revenu
recent aytu made strateg move enter pandem arena highlight
licens exclus distribut right two point-of-car rapid test kit first
hong kong-bas limit licens north american right healgen
scientif houston texas-bas wholly-own subsidiari zhejiang orient gene co ltd
second suppli test kit biolid limit zhejiang orient gene co ltd china-bas high tech
manufactur develop vitro diagnost product clinic test instrument raw materi use
diagnosi biolid limit singapore-bas precis medicin medic technolog compani
focus develop diagnost product
april aytu receiv confirm export approv product shipment china ministri
commerc healgen scientif igg igm rapid test aytu abl purchas
export initi suppli test earli march howev backlog medic product aros
later month china wider lockdown export product test accuraci
specif perform valid uppsala univers uppsala sweden publish
peer-review scientif journal infect ecolog epidemiolog april
biolid igg igm rapid test issu provision author distribut
singapor health scienc author hsa author export aytu commit
purchas test part agreement sign april compani commit
purchas minimum test within first three month agreement aytu biolid
collabor clinic trial design valid biolod rapid test gener data
clearanc fda
 licens
 canada licens
 licens tri
nasal gel drug trt treatment hypogonad
zolpidem tartrat oral spray short-term treatment insomnia
codeine-bas antituss treatment cough cold
mioxsi ce mark
novel vitro diagnost system male infertil assess
acquir cerecor
antihistamin reliev symptom allergi hay fever
acquir cerecor
delayed-releas capsul treatment gerd
acquir cerecor
acquir cerecor
cephalosporin-typ antibiot treat wide varieti bacteri
collaps anti-stat valv hold chamber administ
aerosol medic mdi
acquir cerecor
fluoride-bas multivitamin infant children
acquir cerecor
fluoride-bas multivitamin infant children
acquir innovu
acquir innovu
nasal spray temporari relief season perenni nasal
botan feminin massag oil formul enhanc femal sexual
pleasur arous
acquir innovu
dietari supplement overact bladder urinari incontin
acquir innovu
topic cream reliev pain associ diabet neuropathi
acquir innovu
note concis reason select product shown acquisit innovu result addit product
compet larg therapeut categori includ diabet men health sexual well respiratori health
note publicli trade compani includ aspcf rate
select announc made
complet acquisit innovu pharmaceut
sign exclus distribut right commerci healgen igg igm rapid diagnost test
regain complianc minimum bid price requir
distribut initi healgen igg igm rapid diagnost test
launch regoxidin over-the-counter foam formul minoxidil hair regrowth
announc posit result independ studi healgen igg igm rapid test
public result natesto spermatogenesi studi
sign exclus right distribut biolid igg igm rapid diagnost test
sign develop agreement advanc healight potenti coronaviru treatment
announc result clinic studi igg igm rapid test
announc file emerg use author igg igm rapid test
compani report wainwright estim
bullish aytu bioscienc share base follow three point acquisit innovu
pharmaceut pediatr portfolio asset creat co-promot partnership cross-
sell opportun potenti aytu portfolio legaci product form key platform
diversifi revenu growth potenti distribut right igg/igm rapid
diagnost test kit creat valuabl futur revenu opportun
recent acquisit innovu pharmaceut pediatr product portfolio
creat co-promot partnership cross-sel opportun
think back-to-back acquisit product portfolio innovu within span six
month potenti gener signific momentum base pro forma compani revenu
twelv month end septemb aytu potenti reach million annual revenu
combin organ growth innovu consum health product pediatr product asset
aytu legaci product acquisit busi expand compani
prescript rx portfolio nine differenti product acquisit innovu enabl entri
non-rx consum health market latter portfolio product think recent
acquisit posit step toward aytu transform integr specialti pharmaceut
compani allow cater rx non-rx product segment view expand product
line broaden aytu portfolio beyond million legaci rx therapeut portfolio enabl wider
revenu distribut consum reach reduc season associ aytu season antituss
product line higher revenu expand base proprietari product overal expect
two transact drive busi scale enabl oper synergi leverag multipli
combin compani revenu run-rat acceler time achiev profit support
overhead reduct elimin redund posit increas busi scale
exhibit combin entiti annual revenu potenti million
innovu acquisit key creat portfolio diversif februari aytu
complet acquisit innovu pharmaceut specialti pharmaceut compani focus
commerci licens develop consum healthcar product includ diabet men health
sexual well respiratori health transact aytu retir outstand common stock
innovu certain innovu warrant consider consist approxim million share
aytu common stock approxim two million share prefer stock forgiv
million debt previous owe aytu consolid basi aytu also assum million
unsecur debt innovu addit consider million mileston payment
cash stock come five year
stand-alone compani innovu market sold product product multipl
countri around world intern commerci partner innovu gener revenu
sale commerci product major revenu gener urivarx apeaz
xyralid pevarx beyond human testosteron booster relat product addit innovu
robust pipelin product includ potenti treatment solut muscl sore eye red
hair regrowth cachexia heartburn innovu gener million revenu
prior coverag compani believ innovu track achiev oper break-even
innovu beyond human market sale platform potenti widen aytu market reach
acceler compani timelin profit innovu product portfolio commerci
direct-to-consum market channel util proprietari market sale platform
beyond human use multi-prong approach combin print direct mail magazin on-line
data gain access million potenti consum monthli leverag
follow social media approxim email letter subscrib websit innovu
use platform success launch multipl previous unknown brand multi-million dollar seller
fulli integr line product beyond platform view multi-
prong strategi potenti limit expens fix cost structur compar lower level
versu spend much larger competitor tradit high cost must build
sell market distribut infrastructur
believ aytu benefit innovu alreadi establish sale market network initi aytu
sale forc intend continu handl rx product portfolio beyond market
platform handl consum health product busi howev futur line busi
potenti benefit opportunist cross-sel consum product may market
physician offic set aytu sale forc market rx product may driven
variou on-line direct-to-consum market initi beyond human look
potenti cost save reduc gener administr expens mainli driven elimin
redund administr oper process along reduct overhead administr
facil cost expect cost save materi next sever quarter
innovu acquisit enabl back door entri fast-grow consum product
market along diversifi product portfolio innovu acquisit also provid aytu
opportun tap fast-grow billion consum healthcar product market time
increas number peopl take control healthcar option portfolio over-the-counter
product would help aytu reduc season associ season antituss product
line also allow compani enjoy wider market reach due expand product base think
even small increas share market potenti translat signific revenu
gener compani
exhibit cerecor pediatr primari repres billion market
acquisit commerci portfolio strengthen aytu footprint primari care
prescript segment novemb aytu acquir pediatr portfolio deal valu
excess million consider includ combin cash prefer stock total
million plu assumpt deerfield note total approxim million princip
interest payabl januari deal aytu agre retain commerci infrastructur
sale forc drug acquir along licens suppli direct purchas
agreement acquisit commerci portfolio target billion pediatr rx market
compris six product gener million net revenu purchas portfolio
consist six establish commerci pediatr primari care product includ aciphex sprinkl
cefaclor karbin er flexichamb poly-vi-flor tri-vi-flor
product synergi cross-sel opportun cost save card
busi integr process aytu intend continu evalu implement cross-sel
opportun across product line mani product aytu portfolio
prescrib pediatr famili physician creat abund cross-sel opportun aytu
manag plan conduct extens cross-train natesto former sale
part cost-sav measur optim resourc aytu complet immedi headcount
reduct remov overlap sale repres sale manag redund
employe aytu expect realiz million save annual basi employe
separ transaction-rel expens paid cost save expect result
cash burn reduct approxim across two entiti addit along addit
expens reduct remov redund process commerci servic provid aytu
expect increas product sale acceler growth trajectori newli configur
aytu think time remain scope oper effici achiev subsequ
cost save across compani compani strateg appoint former chief
commerci offic matt phillip compani execut vice presid commerci oper
think would help smoother busi integr would also help maintain
exist growth curv newli ad pediatr portfolio
expect aytu legaci product wit traction form basi grow
divers compani revenu
last six month compani initi sever co-promot activ partner
bode well expand market reach optim sell gener administr expens
aytu amend partnership term royalti payment co-promot
sales-bas commiss natesto per agreement agre fund launch
us-bas sale forc least repres market natesto urologist endocrinologist
strategi intend substanti expand natesto promot footprint enabl aytu increas
promot effort primari care specialti segment recent announc
equiti infus million drive growth natesto moreov believ favor
new commiss structur translat higher gross profit lower mileston payment
regulatori fee clinic trial expens separ also agre assum regulatori
clinic respons associ expens
distinguish clinic profil aytu legaci product strong sell point
compani co-promot agreement poli pharmaceut tuzistra xr expect push
sale uptak increas coverag physician poli field sale repres
nearli doubl aytu promot footprint aim promot approxim prescrib
cough allergi season remind poli geograph footprint cover
approxim antituss rx annual account approxim million annual
revenu separ aytu also enter co-promot agreement
dedic sale forc special psychiatri product rx sleep aid drug zolpimist
believ newli launch co-promot partnership begin yield promis result
come quarter wider market reach higher sale uptak
exhibit aytu exploit cross-sel co-promot opportun
natesto strong clinic profil spermatogenesi studi offer compel advantag
peer natesto nasal gel fda-approv testosteron replac therapi trt
hypogonad low men drug deliv rapidli blood stream via conveni nasal
applic coat insid nostril outer wall lowest fda-approv dose drug
think natesto offer compel advantag altern mainli account rich list
featur includ quick easi painless nasal deliveri method rapid absorpt favor safeti
profil fda black box warn relat transfer man femal partner children
seriou risk associ popular topic administ trt
stori octob top-lin result phase spermatogenesi studi studi
indic men treat natesto hypogonad six month increas serum level
maintain sperm concentr count motil data came contrast form
trt avail market known dramat reduc sperm count render sperm
immotil believ clearli differenti natesto trt translat
bigger market penetr steeper sale trajectori aytu also discuss plan potenti label
modif natesto
compani report wainwright estim
natesto potenti caus disrupt replac market simultan
increas preserv sperm product think natesto clinic profil potenti chang
way hypogonad treat accord report low-t affect around men age
high-valu target custom group demograph account estim
million men low-t repres billion low-t therapi market million
annual rx present fda-approv therapi treat men low testosteron low-t
wish preserv fertil back uniqu product featur favor clinic profil
think aytu well-posit target segment evid natesto total rx jump
versu current reimburs payer plan cover million live expect
increas time natesto compet larg grow testosteron market
compris primarili topic appli treatment form gel solut patch inject
product testopel ave typic implant directli skin physician
androgel market rate market-lead trt alon captur around
half total trt market share howev face gener threat expir key patent
formul begin see gener equival formul product
meaning share trt market includ axiron testim androderm testopel importantli
drug carri black box warn link variou safeti risk
deliveri
note publicli trade compani includ rate
zolpimist tuzistra xr also behind although natesto aytu flagship product compani
show great intent legaci product zolpimist tuzistra xr discuss earlier
co-promot agreement validu poli valid confid brand zolpimist
fda-approv oral spray rx sleep aid avail market serv anoth potenti billion-
dollar market opportun compani zolpimist fast-act formul zolpidem tartrat
wide prescrib rx sleep aid product compet non-benzodiazepin rx sleep
aid segment repres market billion market million rx written annual
interestingli zolpidem tartrat account almost market view zolpimist next
candid line aytu show great potenti product gain traction six-month
end decemb zolpimist rx grew preced six-month period joint-
promot activ place expect see boost rx
aytu legaci product tuzistra xr fda-approv codeine-bas antituss drug
formul long-act antituss target treat cough sever symptom
relat upper respiratori allergi well common cold adult patient billion
market cough cold rx product larg domin short-act treatment requir daili
dose tuzistra xr distinguish peer extended-releas technolog enabl
durat antituss effect offer compel dose advantag current codeine-bas
treatment believ similar natesto zolpimist tuzistra xr bring critic differenti
factor valid prospect becom best-in-class product
mioxsi approv show potenti becom standard care diagnosi
manag male infertil market next line though yet approv
 mioxsi novel rapid semen analysi system diagnosi manag male
infertil caus oxid stress mioxsi alreadi commerci outsid
ce mark clear health canada australian tga mexican cofepra aytu
plan -base clinic trial pursuit de novo medic devic clearanc fda
approv mioxsi would becom first semen analysi diagnost test clear
fda detect oxid stress infertil male infertil preval underserv
condit oxid stress wide implic pathophysiolog male infertil often
unexplain idiopath idiopath infertil frequent associ increas level
oxid stress semen yet diagnost tool exist effect measur oxid stress
level howev antioxid wide avail recommend infertil men without easi accur
assess method avail initi evalu subsequ respons antioxid intervent
 estim around coupl defin infertil male infertil respons
infertil case affect approxim men introduct
mioxsi system could easi effect diagnost tool assess degre oxid
stress potenti enabl monitor patient respons antioxid therapi treatment
regimen male infertil
recent in-licens right distribut igg/igm rapid test kit potenti creat
march aytu gain widespread attent compani join list compani
larg well-establish diagnost test maker offer serolog rapid test kit
aytu igg/igm test result turnaround time minut versu five minut competitor
next fastest test result turnaround time five minut believ aytu rapid test
differenti increasingli crowd rapid diagnost test market notabl first
test alreadi purchasedevid huge unmet demand thu although past
pandem eventu end on-going pandem expect end someday
believ aytu access right distribut igg/igm rapid test kit creat valuabl potenti
near-term possibl long-term futur revenu opportun aytu underappreci
aytu first test kit alreadi distribut point huge unmet
demand march aytu announc secur exclus distribut right covid-
igg/igm rapid test kit ltd hong kong corpor licens north
american right china-bas product develop zhejiang orient gene biotech co ltd zogb
make test kit avail healgen scientif hs zogb houston texas-bas
wholly-own subsidiari zogb igg/igm rapid test solid phase immune-chromatograph
assay intend rapid qualit differenti detect igg igm antibodi sars-cov-
emerg previous refer whole blood serum plasma
april aytu announc receiv confirm export approv china ministri
commerc shipment addit rapid test kit compani warehous
bolster confid compani suppli chain think igg/igm test kit
abil deliv close real-tim result within minut point-of-car key differenti
product diagnost market gradual becom crowd multipl player
april aytu announc sign definit agreement exclus distribut
ncov igg/igm test kit rapid test deliv result minut develop
singapore-bas biolid limit biolid igg/igm rapid test issu
provision author distribut singapor health scienc author hsa author
export singapor term agreement aytu commit purchas test
within one busi day date sign agreement addit compon aytu
exclus compani commit purchas minimum test within first three month
agreement aytu collabor biolid conduct clinic trial plan complet
obtain fda regulatori file clearanc igg/igm rapid test believ
togeth export rapid test china aytu strengthen suppli chain potenti
sale igg/igm rapid test kit initi drew controversi aytu secur
exclus distribut right igg/igm rapid test kit aytu receiv
signific critic scrutini healgen gain formal fda approv commerci test kit
 gain fda emerg use author eua briefli eua allow fda help strengthen
nation public health protect chemic biolog radiolog nuclear cbrn threat
facilit avail use medic countermeasur mcm need public health
emerg pandem earli fda polici issu februari eua
igg/igm rapid test allow test develop kit import allow import
legal bring test kit market specif use determin blood level antibodi sars-
initi valid aytu test establish posit clinic trial
support ce mark europ although aytu igg/igm rapid test also initi
regulatori approv china believ rapid test gener signific regul interest one
test use coronaviru screen china rapid test export later bar
march due explod number case china countri need maintain adequ test
capabl nation secur purpos howev note aytu alreadi order test kit
distribut ship becam avail back fda polici announc
februari distribut fda updat polici final fda
sinc updat polici may issu final guidanc industri document
think import note februari polici issu given natur covid-
public health emerg fda specifi critic agenc provid regulatori
flexibl serolog test develop understand test meant use
sole basi diagnosi coronaviru antibodi test subsequ enter
market fuel congression investig accuraci test fda tighten
requir compani develop antibodi test effort combat fraud better
regul frenzi test come market updat polici requir commerci antibodi test
develop appli eua fda tight time-frame also provid specif perform
threshold recommend test specif sensit revis requir follow march
polici allow develop valid test bring market without
agenc review specif new approach requir commerci manufactur submit eua
request valid data within busi day date notifi fda
valid test date polici issu may whichev later addit
fda provid specif perform threshold recommend specif sensit serolog
serolog igg
serolog igg igm
serolog igg igm
serolog igg igm
serolog igg
serolog igg
serolog igg
serolog igg
serolog igm igg
review process valid
igg/igm test serolog igg igm
serolog igg igm
note statu eua applic may abbott rate roch rhhbi rate euroimmun
rate compani
fda compani report wainwright
expect valid studi set apart qualifi assay sub-par assay result fda
final guidanc industri specifi clinic serolog test agenc defin test
identifi antibodi igg igm clinic specimen valid prior
use guidanc specifi context current public health emerg critic
import test valid fals result neg impact individu patient
also broad public health impact recommend valid studi conduct includ
studi cross-react analyt specif class specif clinic agreement clinic
agreement studi intend establish perform characterist sensitivity/ppa
specificity/npa test fda recommend clinic accuraci establish human
specimen patient microbiolog confirm thu antibodi
test current subject pre-eua eua review antibodi test author
individu eua
aytu in-licens igg/igm rapid test point-of-car later flow immunoassay initi
evalu use blood sampl collect pcr-confirm patient neg
patient differ clinic site china includ wuhan consortium scientist led
guangzhou institut respiratori health re-evalu member
consortium use sampl obtain patient exhibit pneumonia respiratori
kit use drop blood simpl finger prick provid faster result nasal
swab produc result take hour turn around sampl test use
zogb diagnost devic compar rt-pcr clinic diagnosi includ chest comput
tomographi scan clinic sign symptom pneumonia caus
emerg previous refer sensit igm test
specif compar rt-pcr sensit igg test
convalesc recoveri period specif
exhibit comparison igm result
exhibit comparison igg result
accuraci specif perform igg igm rapid test evalu
uppsala univers uppsala sweden work support swedish research council
sweden largest government research fund bodi studi full result publish
scientif journal infect ecolog epidemiolog april use support ce mark
approv commerci sale europ sweden-bas novir ab donat test uppsala
scientist uppsala evalu test pcr-confirm case
neg control result reveal sensit igm igg respect base
sole pcr-posit due absenc serolog gold standard compar result
initi evalu igg igm rapid test uppsala result show lower sensit
igm similar sensit igg specif fell result two evalu
assay specif igm fals posit igg use
pcr-posit case true posit accuraci test
igm igg respect posit neg predict valu likelihood
case given posit result likelihood healthi given neg test result igm
respect igg correspond valu
respect
exhibit pcr-posit case posit neg vs day onset symptom
note onset group patient day group day
pcr-posit case antibodi may yet time develop potenti case
immun defect possibl neg igm igg result fact true neg notabl
case one includ patient evalu sampl
known contain detect level igm igg actual sensit would
higher optim evalu assay sensit gold standard
antibodi could use quantifi titer neutral antibodi viru would need
howev gold standard current avail
studi investig remark neg result may unreli first week
infect believ result indic aytu igg igm rapid test suitabl
assess previou viru exposur lastli line fda guidanc aytu recommend second test
use rt-pcr conduct peopl test posit rapid test
pandem continu coronaviru test still remain short suppli lot
conjectur valu antibodi test therefor much research on-going
type test offer help us understand regard cours on-going pandem
well develop immun thu develop serolog assay
accur assess prior infect immun consid essenti
epidemiolog studi on-going surveil vaccin research develop potenti risk
assess healthcar essenti consid role play diagnost test
bridg futur avail cov vaccin thu repres potenti opportun
recur revenu long pandem continu
may john hopkin univers center system scienc engin csse
dashboard report test conduct accord
center diseas control prevent cdc confirm case covid-
howev countri popul may make rate
test per million mark improv littl ago april
test per million peopl begin march five test per million peopl
conduct scope outbreak suggest still signific number
peopl infect miss report world organ state sign
mani case havent found commun coronaviru test
come back posit found peopl test posit signific number case
probabl miss posit mean test use mainli confirm
obviou case result health author get clear pictur scope epidem
area report state place everi close contact suspect case
test percent neg case high countri extens test fewer
test exampl may south korea conduct estim
test half conduct earli april contrast south korea
three percent test come back posit percent posit test
rang state new york reportedli high workforc meat pack
plant iowa thu need coronaviru test may like remain high long
percentag posit remain high cdc may abl specifi much test
need one follow who benchmark posit test rate would
need conduct million test creat pictur full scope outbreak
popul expert epidemiolog pubic health call million test day late
juli fulli remobil believ repres signific unmet medic need
avail aytu approxim million rapid test avail could play meaning role
diagnost market present ampl potenti futur growth thu market
opportun multipl entrant mani player express plan launch coronaviru test
expect see list eua grow thu expect aytu compet mani player within
diagnost serolog includ big player roch rhhbi rate abbott
rate whose presenc term distribut channel brand name recognit well sale
market budget signific challeng result aytu rapid test busi could
near-term opportun long remain shortag test avail thu
acknowledg may earli view aytu rapid test long-term impact busi
nevertheless believ compani entri coronaviru diagnost market place aytu
micro-cap compani limit commerci reach market posit take advantag
signific near-term market opportun although aytu face direct competit larger
player believ diagnost market sizeabl could easili provid room entri
multipl player new market like aytu addit recogn competit
small upcom coronaviru test kit manufactur well believ quick turnaround time
aytu rapid test well strong valid result aytu test gener posit compani
strong competitor lastli fda final guidanc requir test maker show test meet
agenc paramet approv believ subpar test result aytu competitor narrow
play field creat opportun aytu achiev market share possibl maintain
meaning market share long term therefor even small penetr market would
substanti impact compani revenu believ aytu rel small size compar
peer work favor remain underappreci
polici coronaviru test public health emerg revis may
hopkin univers center system scienc engin csse dashboard
diseas control prevent cdc statist coronaviru diseas case
who-china mission coronaviru diseas www int/docs/default-
univers roadmap pandem resili www ethic harvard edu/covid-roadmap
use discount cash flow dcf methodolog arriv price target aytu
bioscienc aytu share specif discount free cash flow year
compani weighted-averag cost capit wacc divid project number share
year account effect share dilut use termin growth rate probability-
of-success deriv adjust per share valu round assumpt
made includ
new innovu product approv per year innovu accomplish past three year
sale market expens growth annual growth rate initi high growth phase
project fiscal
gener administr expens growth annual growth rate initi high growth
phase project fiscal
initi sale igg igm rapid test fiscal sale price per test
consid conserv retail price current avail antibodi test cost low
per test abbott igg assay per
distribut six million rapid test fiscal test annual thereaft
cumul averag growth rate compound-annual-growth-rate portfolio innovu product
aytu product depend new product approv product
million total financ conduct date averag price averag
price per share fiscal year-end share count million share
discount rate wacc
termin growth rate believ conserv believ annual price increas
possibl compani product expect addit futur product
acquisit
lastli probabl success weighted-averag success rate observ rx-
to-otc applic specialti pharmaceut gain regulatori
compani report wainwright co estim
aytu portfolio- acquir portfolio- innv acquir portfolio- royalties- collabor licens total sg depreci stock-bas interest provis incom taxes- chang work free number share per termin valu per share- round todiscount growth npv per npv termin valu per valu per probabl probabl aytu bioscienc inc
clinic although compani product requir nomin clinic test may requir
specif clinic trial design order meet fda requir approv possibl
product fail test would materi affect valuat
regulatori even rx-to-otc switch product met requir regulatori approv
possibl new regul creat address linger safeti efficaci concern
occur could significantli delay revenu gener go forward could materi affect
forecast addit even compani rapid test demonstr high sensit
specif antibodi guarante product gain eua
commerci success implement aytu commerci strategi requir sustain
near-term revenu growth support growth compani sell market distribut effort
failur commerci strategi could result signific stock price declin
competit aytu commerci strategi fail demonstr differenti possibl may
competit inde doctor consum may continu favor use brand
prescription-onli product could materi affect forecast case compani
rapid test may show adequ differenti
intellectu properti rx-to-otc switch product significantli reli intellectu properti
protect aytu significantli reli brand specialti product regist trademark
copyright materi sustain long-term revenu potenti weak strength
could significantli diminish compani abil realiz product revenu project key
anticip compani pro forma cash posit million adequ
fiscal possibl addit fund may requir current futur sell market
distribut expens innovu product may requir rais capit poor market condit
compani report wainwright co estim
incom statement fiscal year end june except per share product aytu bioscienc inc aytu acquir innovu pharmaceut inc innv acquir royalti income- licens revenue- total good gross sg impair intang amort intang oper oper incom expens derecognit conting consider warrant deriv pre-tax incom tax benefit expens others- net incom ep weight averag aytu bioscienc inc
compani report wainwright co estim
incom statement fiscal year end june except per share product aytu bioscienc inc aytu acquir innovu pharmaceut inc innv acquir royalti income- licens revenue- total good gross sg impair intang amort intang oper oper incom expens derecognit conting consider warrant deriv pre-tax incom tax benefit expens others- net incom ep weight averag aytu bioscienc inc
compani report wainwright co estim
incom depreci amort stock compens capit free net chang aytu bioscienc inc
compani report wainwright co estim
balanc sheet cash restrict prepaid expens current account receiv note receivable- current total current total sharehold liabil aytu bioscienc inc
materi confidenti intend use institut account defin finra rule may also
privileg otherwis protect work product immun legal rule receiv mistak pleas let
us know email repli delet system may copi messag
disclos content anyon integr secur messag guarante internet
 wainwright co llc rate wainwright employ three tier rate system evalu
potenti return risk associ own common equiti share rate firm expect return given
equiti measur rel basi compani sector price object calcul estim
potenti movement price given equiti could reach provid certain target met defin time horizon
price object subject extern factor includ industri event market volatil
market outperform buy common stock compani expect outperform passiv index compris
common stock compani within sector
market perform neutral common stock compani expect mimic perform passiv index
compris common stock compani within sector
market under-perform sell common stock compani expect under-perform passiv index compris
common stock compani within sector
rate price target histori aytu bioscienc inc aytu-u
rate price target histori inc cerc-u
relat compani mention report
invest bank servic includ limit act manager/co-manag underwrit placement
secur act financi advisor and/or provid corpor financ capit markets-rel servic compani
one affili subsidiari within past month
distribut rate tabl may
 wainwright co llc firm member finra sipc regist broker-deal
vernon bernardino certifi view express report accur reflect person view
subject secur issuer discuss part compens directli indirectli relat
specif recommend view express research report neither member
household offic director advisori board member compani
none research analyst research analyst household financi interest secur aytu bioscienc
inc inc includ without limit option right warrant futur long short posit
april neither firm affili benefici class common equiti secur
aytu bioscienc inc inc
neither research analyst firm know reason know materi conflict interest time
public research report
research analyst princip respons prepar report receiv compens base upon
specif invest bank servic transact compens base factor includ total revenu profit
firm substanti portion deriv invest bank servic
firm affili receiv compens inc non-invest bank servic previou
firm affili receiv compens aytu bioscienc inc inc invest bank servic
within twelv month seek compens compani mention report invest bank
servic within three month follow public research report
 wainwright co llc manag co-manag public offer secur aytu bioscienc inc
inc past month
firm make market aytu bioscienc inc inc date research report
secur compani discuss report may unsuit investor depend specif invest
object financi posit past perform guarante futur result report offer inform
purpos constitut offer solicit buy sell secur discuss herein jurisdict
would prohibit research report intend provid tax advic use provid tax advic
person electron version wainwright co llc research report made avail client simultan
part report may reproduc form without express permiss wainwright co llc addit
 wainwright co llc provid individu tailor invest advic research report research report
intend provid person invest advic take account specif invest object financi
situat particular need specif person investor seek financi advic regard appropri
invest financi instrument implement invest strategi discuss recommend research report
 wainwright co llc affili salespeopl trader profession may provid oral written market
commentari trade strategi reflect opinion contrari opinion express research report
 wainwright co llc affili offic director employe exclud analyst time time
long short posit act princip buy sell secur deriv includ option warrant
thereof cover compani refer research report
inform contain herein base sourc believ reliabl guarante us
accur purport complet statement summari avail data compani industri secur
discuss report opinion estim includ report constitut analyst judgment date
report subject chang without notic
secur financi instrument discuss research report may lose valu insur feder
deposit insur corpor subject invest risk includ possibl loss princip amount invest
